Bedaquiline Fumarate

證據等級: L5

預測適應症: 0 個

Bedaquiline Fumarate: Drug Repurposing Evaluation — No Predicted Indication Identified

One-Sentence Summary

Bedaquiline fumarate is a marketed drug in Malaysia with 1 registered licence; however, the approved indication text was not captured in the current data extraction. The TxGNN model did not generate any repurposing predictions for this compound, and significant data gaps remain in safety, mechanism of action, and regulatory detail, preventing meaningful evaluation at this time.

Quick Overview

Item	Content
Original Indication	(Not captured in current data — see Data Gaps below)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (No prediction, no supporting studies)
Malaysia Market Status	✓ Marketed (已上市)
Number of Registrations	1
Recommended Decision	Hold

Why Was No Prediction Generated?

Bedaquiline fumarate is a diarylquinoline antimycobacterial agent primarily indicated for the treatment of multi-drug resistant tuberculosis (MDR-TB). It works by inhibiting mycobacterial ATP synthase, a mechanism highly specific to Mycobacterium tuberculosis.

The TxGNN knowledge graph model returned zero repurposing candidates for this drug. Several factors may explain this:

Missing DrugBank ID mapping: The evidence pack shows drugbank_id: null. Without a valid DrugBank identifier, the drug cannot be located within the TxGNN knowledge graph (which relies on DrugBank nodes), effectively excluding it from the prediction pipeline.
Narrow mechanism specificity: Bedaquiline’s target — mycobacterial ATP synthase — is structurally distinct from the human mitochondrial ATP synthase. This high target specificity may limit the model’s ability to identify plausible disease–drug edges in the knowledge graph.
Incomplete input data: The original indication text, MOA, and safety fields are all missing or flagged as [Data Gap], further reducing the information available for prediction.

Clinical Trial Evidence

Currently no repurposing-related clinical trials to report, as no new indication was predicted.

Literature Evidence

Currently no repurposing-related literature to report, as no new indication was predicted.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Not captured)	(Not captured)	(Not captured)	(Not captured)

Note: The NPRA query returned 1 licence (query date: 2026-03-27), but the licence detail fields (number, product name, dosage form, indication) were not populated during data extraction. Manual verification on the NPRA Quest database is recommended.

Safety Considerations

Please refer to the package insert for safety information. All safety fields (key warnings, contraindications, drug interactions) were not available in the current evidence pack.

Data Gaps Summary

The following critical data gaps were identified and should be resolved before re-evaluation:

Gap ID	Item	Severity	Impact	Remediation
DG001	TFDA Label Warnings / Contraindications	Blocking	Cannot enter S1 safety screening	Download and parse label PDF from regulatory authority website
DG002	Mechanism of Action (MOA)	High	Affects mechanism–indication relevance analysis	Query DrugBank API (bedaquiline → DB09034)
—	DrugBank ID	High	Drug excluded from TxGNN knowledge graph	Map BEDAQUILINE FUMARATE → DB09034 and re-run prediction
—	Approved Indication Text	Medium	Cannot establish baseline indication	Re-query NPRA or extract from product label

Conclusion and Next Steps

Decision: Hold

Rationale: No repurposing candidates were generated by TxGNN, most likely because the drug could not be mapped into the knowledge graph (missing DrugBank ID). Multiple blocking data gaps prevent safety evaluation. This candidate cannot proceed until foundational data is resolved.

To proceed, the following is needed:

Resolve the DrugBank ID mapping (bedaquiline fumarate → DB09034) and re-run the TxGNN prediction pipeline
Extract the approved indication text from the NPRA product label or Quest database
Obtain the package insert to populate safety warnings, contraindications, and drug interaction data
Re-generate the evidence pack with complete fields before re-evaluation

Disclaimer: This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.